1. Transarterial Embolization With Cyanoacrylate for Severe Arterioportal Shunt Complicated by Hepatocellular Carcinoma
- Author
-
Zheng-Qiang Yang, Lin-Bo Zhao, Wei-Zhong Zhou, Hai-Bin Shi, Chun-Gao Zhou, Jin-Guo Xia, Sheng Liu, and Lin-Sun Li
- Subjects
Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,medicine.medical_treatment ,Arteriovenous fistula ,Statistics, Nonparametric ,law.invention ,Liver Function Tests ,law ,Carcinoma ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Cyanoacrylates ,Embolization ,Survival rate ,Aged ,Proportional Hazards Models ,Retrospective Studies ,medicine.diagnostic_test ,Portal Vein ,business.industry ,Liver Neoplasms ,Angiography ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Embolization, Therapeutic ,Survival Rate ,Treatment Outcome ,Cyanoacrylate ,Hepatocellular carcinoma ,Arteriovenous Fistula ,Female ,Radiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
To evaluate the efficacy and safety of cyanoacrylate glue embolization in the treatment of severe arterioportal shunt (APS) presenting with hepatofugal portal venous flow in hepatocellular carcinoma (HCC) patients. Between July 2000 and January 2010, 27 HCC patients with severe APS presenting with hepatofugal portal venous flow underwent transarterial angiography and treatment. Among them, four patients were excluded from the study. Twelve patients underwent transarterial chemoperfusion and embolization of APS with cyanoacrylate glue between January 2006 and January 2010 (Emb group), and the other 11 patients undergoing only transarterial chemoperfusion without embolization of APS between July 2000 and December 2005 served as a control group (non-Emb group). The change of APS, survival rates, and procedure related complications were analyzed. In the Emb group, APS was improved in all of the 12 patients after initial glue embolization; long-term APS improvement with hepatopetal portal flow was achieved in 80 % (8 of 10) patients who underwent follow-up angiography. Survival rates in the Emb group were 67 % at 6 months, 33 % at 1 year, and 8 % at 2 years, whereas those in the non-Emb group were 0 % at 6 months (P
- Published
- 2012